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Abstract Recent developments in in vitro disease modeling
and regenerative medicine have placed induced pluripotent
stem cells (iPSCs) in the center of attention as a unique
source to study Parkinson’s disease. After only 5 years of
intensive research, human iPSCs can be generated without
viral integration and under xeno-free conditions. This, com-
bined with increasingly sophisticated methods to differenti-
ate iPSCs into functional dopaminergic (DA) neurons, led
us to recapitulate the most important findings concerning the
use of iPSC technology as a prospective tool to treat symp-
toms of Parkinson’s disease as well as to obtain insight in
disease related cell pathogenesis. Moreover, we touch upon
some of the latest discoveries in which patient-derived au-
tologous DA neurons come into even more direct reach
thanks to a method that allows transdifferentiation of fibro-
blasts into DA neurons.
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The Rise of Induced Pluripotency
The discovery of induced pluripotent stem cells quickly
developed into one of the most competitive and most so-
phisticated research areas in biology. In 2006, a key study
by the group of Shinya Yamanaka showed for the first time
that somatic cells, such as murine embryonic fibroblasts
(MEFs), could be reprogrammed to a pluripotent, embryon-
ic stem (ES) cell-like state [1]. This epigenetic reprogram-
ming event in fibroblasts was driven by viral delivery of
four transcription factors (hereafter referred to as ‘Yamanaka
factors’), namely Oct4, Sox2, Klf4 and cMyc. It became
clear that when these genes successfully integrated into the
genome of a host cell and expression occurred in an optimal
stochastic manner, the virus transfected cell changes from a
differentiated somatic cell into a pluripotent stem cell, which
in turn is able to differentiate into every cell type of the
body. Shortly after this groundbreaking discovery several
other groups confirmed and reported the generation of
iPSCs. Procedural optimization steps have been undertaken
thereafter for example by using a more suitable selection
marker for the reprogrammed induced pluripotent stem cells
Oct4 or Nanog [2] instead of Fbx15 (used by the Yamanaka
group) or even by identifying iPSC colonies merely on their
morphology instead of the use of genetically modified fibro-
blasts as starting material [3]. IPSCs generated by this
epigenetic reprogramming process have been characterized
and identified as truly fulfilling the criteria for pluripotency
within a very short time span. Thus, iPSCs were not only
able to differentiate into cell types from all three germ layers
(mesoderm, endoderm and ectoderm) and to contribute to
embryo formation after injection in a blastocyst (chimeric
mice), they could also contribute to the germ line in such a
setup. Moreover, they formed teratomas after subcutaneous
injection or subcapsular implantation in the testis or kidney
[4, 5]. Last but not least, as one of the most stringent criteria
for pluripotent cells, iPSCs have been injected in a tetraploid
blastocyst, which was subsequently implanted in a surrogate
mother mouse, where they gave rise to so called ‘all-iPS
mice’, viable mice that exclusively originated from the
implanted iPSCs, via a process called tetraploid comple-
mentation [5, 6].
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The next major step in iPSC research was the discovery
that also human somatic cells could be reprogrammed into
iPSCs using a similar approach and with similar properties
as mouse iPSCs [7, 8].
Due to the extremely rapid development in this particular
research field, iPSCs became highly interesting tools for in
vitro disease modeling but also for potential application in
regenerative medicine. However, the reprogramming proce-
dure itself was bearing a crucial and very undesirable com-
ponent. IPSCs so far were generated by use integrating
viruses that intrinsically modified the genome of the host
cells. Especially the integration of oncogenes such as cMyc
and Klf4 would not be acceptable for any clinical applica-
tion of iPSC-derived cells or tissues. In order to avoid this
hurdle, several methods have been tested to circumvent viral
integration events. First attempts were directed to reduce the
number of integrating proviruses e.g. by eliminating Myc
transduction [9], but also the generation of iPSCs with non-
integrating adenoviruses and temperature sensitive Sendai
viruses has been tested and proven possible [10, 11]. In a
next logical follow up step, the use of viruses has been
abandoned completely by utilization of direct repeated
transfection with ‘Yamanaka factor’ containing plasmids
[12] or piggyback transposons [13]. Another interesting
approach is the use of microRNAs (miRs) to drive induction
of pluripotency. Anokye-Danso et al. [14] showed that two
specific miRs (miR302 and miR367) are sufficient to induce
pluripotency in mouse and human somatic cells without
forced expression of exogenous transcription factors [14].
Even more towards a safe clinical use is the induction of
pluripotency with RNA molecules that code for the four
‘Yamanaka factors’ [15]. Eventually it has been shown that
iPSCs can also be generated by direct Oct4-, Sox2-, Klf4-
and cMyc- protein delivery to human fibroblasts [16].
In general it seems that technical safety issues that previ-
ously hampered the use of iPSCs for a wide variety of clinical
applications are about to be solved. In the scope of this review
these developments are particularly interesting for the in vitro
generation of iPSC derived DA neurons (Fig. 1).
Mouse iPSCs as Crucial Model System
Mouse as well as human iPSCs have been shown to be capable
to differentiate into varying clinically relevant cell types, such
as cardiomyocytes [17, 18], hepatocytes [19], hematopoetic
progenitors [20], oligodendrocytes [21] and specific subtypes
of neurons [22, 23]. In particular, iPSC-derived DA neurons
appear to be a very interesting, clinically relevant cell type (for
overview of key studies see Table 1). First, they might serve as
novel easily accessible autologous source for cell replacement.
Many studies, starting in the 1980s, have already demonstrated
that the consequences of the specific loss of midbrain DA
neurons in the substantia nigra pars compacta (SNc), the
hallmark of Parkinson’s disease, can be partly obviated by
the intrastriatal implantation of extrinsic (heterologous)
abortion-derived fetal human DA neurons [24–26]. Although
this approach itself appeared to be successful, major practical
and ethical concerns related to the use of this fetal human graft
source were unbridgeable and made this strategy not feasible
for the clinic [27, 28].
Secondly, iPSC derived DA neurons provide a unique
tool to investigate cell pathogenic mechanisms in detail (e.g.
the role of α-synuclein or LRRK2, etc.), particularly when
the iPSCs are generated from patients with a hereditary form
of Parkinson’s disease [29, 30].
Before the iPSC technology entered the playground, DA
neuron differentiation has been extensively studied for embry-
onic stem cells (ESCs) and neural stem cells (NSCs), either
derived from ESCs [31, 32] or primary isolated [33, 34]. In
order to improve in vitro generation of DA neurons derived
from ESCs protocols have been developed that enhance DA
differentiation. Early approaches involved the use of stromal
feeder layers (such as MS5 or PA6 cells) [35, 36]. Later, in
order to avoid undefined factors, protocols have been estab-
lished that employ small molecules and recombinant proteins
which specifically inhibit BMP signaling pathway (dual inhi-
bition of SMAD signaling) [37]. Recent studies provide evi-
dence that derivation of floor plate cells (the floor plate is a
crucial organizing structure in the developing embryo, located
along the ventral midline) from pluripotent stem cells, by early
supplementation with high concentrations of sonic hedgehog
and induction of canonical Wnt signaling by small molecules,
drastically improves the quantity and quality of subsequently
generated DA neurons [38, 39].
Based on established methods for in vitro differentiation of
DA neurons efficient protocols for dopaminergic differentia-
tion of iPSCs have been developed. One of the first studies by
Wernig et al. [22] showed successful generation of DA neu-
rons derived from mouse iPSCs [22]. These cells showed
some specific DAmarker expression, such as the transcription
factors Nurr1, Pitx3 and the enzyme tyrosine hydroxylase
(TH). Furthermore, they revealed typical neuron-like electro-
physiological properties and they functionally integrated in a
rat model for PD after transplantation. However, the number
of DA neurons that could be generated did not exceed 4 % of
the starting iPSC population, indicating that most of the cells
that developed with that differentiation procedure had non-
DA characteristics. While the study provided the proof of
principle for treating PD symptoms with iPSC derived DA
neurons in an animal model, various important issues were not
or could not be addressed. Firstly, since only a minority of
grafted iPSC derived cells were DA neurons, it can be ques-
tioned what the effect was of the vast majority of other cell
types in the graft; it is clear that some kind of purification step
is required. Secondly, in view of the exceptional origin of the
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DA neurons, characterization of the iPSC derived DA neurons
and assessment of the completeness and stability of differen-
tiation should not only be based on a set of general DA
markers and electrophysiological characteristics, but should
also contain extensive genetic and epigenetic screening. The
challenge for a more comprehensive study of epigenetic and
genetic characteristics of iPSC derived DA neurons mainly
lies in the necessity to generate a cell population that allows
purification based on a highly specific midbrain DA marker.
Earlier studies reported the generation of ESC lines with
specific heterozygous GFP knock-in modification in the
dopamine transporter (DAT) locus and the Pitx3 locus [40,
41]. Both genes code for specific DA markers. Pitx3 is a
transcription factor specifically expressed in mDA neurons,
that interacts with Nurr1 and is crucially involved in differen-
tiation and maintenance processes for mDA neurons [42–45].
DAT is widely expressed in DA neurons and specifically
indicates their maturation [46]. However, because of its
general function in DA neurons (residing e.g. in the olfactory
bulb or the ventral tegmental area) DAT cannot be considered
as a selective marker for mDA neurons.
Our group has used Pitx3-GFP knock-in mice (kindly
provided by Prof. M. Smidt, SILS, University of Amsterdam)
for the generation of iPSC lines. The Pitx3-GFP knock-in
Fig. 1 Schematic comparison between iPSC technology and trans-
differentiation to generate DA neurons in vitro. IPSC technology
requires a forced expression/induction (either by viral transduction,
RNA or protein transfection) of Oct4, Klf4, Sox2 and cMyc. Recent
DA differentiation protocols provide robust yields of neurons highly
resembling DA neuron characteristics. Directly converted neurons are
not derived from a pluripotent intermediate, which minimizes unde-
sired differentiation potential and risks for teratoma formation. DA-like
neurons generated so far however show only very limited resemblance
with primary midbrain DA neurons
Table 1 Key studies for in vitro generation of DA neurons/iDA neurons from pluripotent stem cells and somatic cells (trans-differentiation),
respectively
Species Viral integration Pluripotent stem cells Characterization Reference
Mouse Yes iPSCs DA markers, electrophys.properties, functional integration [22]
Human No (direct protein delivery) human iPSCs DA markers, electrophys. Properties, DA release,
functional integration
[51]
Human Yes(Cre-excised) iPSCs (patient specific) DA markers [52]
Human Yes(Cre-excised) iPSCs (patient specific) DA markers, functional integration (6OHDA rats) [53]
Human No (Sendai virus) ESCs/iPSCs Floor plate based DA induction, DA gene expression profile,
electrophys. properties, functional integration
[39]
Species Viral integration Trans-differentiation Characterization Reference
Mouse Yes transdiff. fibroblasts iDA neurons DA markers (TH selection) electrophys.properties, DA
release, global gene expression (TH sorted),
functional integration
[62]
Mouse Yes transdiff. fibroblast iDA neurons DA markers (Pitx3 selection), electrophys.properties, DA
release, selected gene expression (Pitx3 sorted),
functional integration
[69]
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feature allowed us selective isolation, identification and puri-
fication of primary embryonic and postnatal mDA neurons as
well as of DA neurons that were obtained via differentiation of
the iPSCs (see Fig. 2). This approach enabled us to perform an
extensive comparison of iPSC-derived DA neurons with pri-
mary mDA neurons (including varying developmental stages)
as far as their genetic and epigenetic profiles are concerned.
We particularly focused on DNA methylation, since reprog-
ramming of somatic cells towards pluripotent cells and sub-
sequent differentiation into DA neurons must entail massive
changes in DNAmethylation patterns in specific genomic loci
[47–50]. This type of characterization, which was based on
the ability to analyze purified Pitx3-GFPDA neurons, enabled
us to determine a close similarity in terms of DNA methyla-
tion patterns between iPSC-derived DA neurons and primary
DA neurons and provides novel insight in cell type specific de
novo methylation during in vitro differentiation (Roessler et
al., manuscript in preparation). Before human iPSC-derived
DA neurons might serve as tool for future cell replacement
approaches such detailed in depth-studies will certainly be
required in order to assure their clinically safe status as well
as their bona fide characteristics. It will however remain
difficult to directly compare human iPSC-derived DA neurons
tor their primary counterpart.
Human iPSCs to Study and Treat PD
Clinical application of iPSC-derived DA neurons for treat-
ing Parkinson’s disease is still a distant option. All the
aforementioned issues concerning the clinically safe use of
iPSCs as well as the incomplete characterization of in vitro
generated DA neurons form prominent roadblocks that re-
main to be cleared. A recent study provides evidence that
human iPSCs completely free of proviruses (these hiPSCs
were generated by direct protein delivery) are efficiently
capable to differentiate towards functional DA neurons
[51]. Such patient-derived iPSCs will provide a valuable
tool for possible future cell based therapy approaches.
Soldner et al. [52] were the first to generate human iPSCs
(hiPSCs) cells from patients with idiopathic PD [52]. Their
study showed that indeed reprogramming factor-free iPSCs
could be generated from PD patients using Cre-recombinase
excisable viral constructs. Moreover, those patient-specific
iPSCs could be differentiated in tyrosine hydroxylase (TH)-
expressing neurons. In a follow-up study, PD patient iPSC-
derived TH expressing neurons have been transplanted in a
PD rat model (6-OHDA), where they reduced specific
neurotoxin-induced asymmetric motor behavior [53]. These
studies demonstrate the capability of hiPSCs to differentiate
into functional neurons that improve PD symptoms associ-
ated with reduced dopamine signaling in the striatum. How-
ever, more extensive research needs to be done to further
characterize patient-specific iPSC derived DA neurons in
terms of the completeness and stability of their differentiated
state. For that, global gene expression studies but also, as
mentioned above, in-depth studies of epigenetic character-
istics such as DNA methylation and histone modifications
are required before clinical application will come within
reach.
Regarding the use of patient-specific iPSC-derived DA
neurons as in-vitro PD model, it should be considered that
PD is in general a late onset disease, which affects patients
after decades of latent disease progress. Therefore, it may be
quite challenging to model PD in vitro. Slowly developing
molecular changes such as α-synuclein aggregation in pa-
tient derived DA neurons might not be detectable in cell
culture that at best can be maintained for a few month.
Fig. 2 Pitx3-GFP iPSC derived mDA neurons show co-expression of
transgenic GFP (Pitx3gfp/+) and Map2 (a) as well as tyrosine hydrox-
ylase (TH) (b). Confocal microscopy (b) revealed that most of the
Pitx3 expressing cells also express TH. However TH positive cells do
not always show Pitx3 expression
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Moreover, genetic variations intrinsic to patient-specific
iPSCs could complicate disease modeling since it will be
literally impossible to generate experimentally defined con-
ditions. A very interesting approach in that respect is a
technology known as ‘genome editing’, employing zinc
finger nucleases (ZFNs) to site-specifically target a disease
relevant gene. Soldner et al. [54] used ZFNs in patient-
specific iPSCs to exclusively manipulate a point mutation
site in the α-synuclein gene known to be key in rare forms
of familial PD [54]. Mutations in α-synuclein at specific
sites (e.g.: A53T; E46K or A30P) lead to the formation of
Lewy bodies, which are inclusions present in affected DA
neurons (for reviews on α-synuclein and Lewy bodies see
e.g. [55, 56]). In this study by Soldner and colleagues [54]
these mutations have been addressed with genome editing
aiming either at correction of a specific mutation (e.g. in PD
patient specific hiPSCs) or vice versa at generation of
a mutation (e.g. in wild-type ES cells) in order to study
cell pathogenic consequences of such disease relevant
modifications.
Even though, DA neurons generated from human iPSCs
do not easily allow purification as indicated for transgenic
mouse iPSC-derived DA neurons, a thorough characteriza-
tion is extremely crucial. Conceivable approaches also
involve genome editing. ZFNs (as described above) and
transcription activator-like effector nucleases (TALENs)
have been used to genetically engineer human iPSCs that
contain the GFP coding sequence (either 2A-eGFP or
eGFP) in the locus of the Pitx3 gene [57, 58]. As yet,
however no study showed the purification of Pitx3-GFP
cells derived from ZFNs- or TALENs-modified human
iPSCs. Succeeding in such a purification step will certainly
improve the possibility to study specific molecular mod-
ifications (e.g. mutations in the α-synuclein- or LRRK2-
gene) and their consequences in affected cells. It might
also allow to find changes in cells bearing disease relevant
modifications before phenotypic (pathological) changes
are detectable.
Towards a Direct Patient Specific Cell Replacement
Strategy
Very recent studies report about the direct conversion or
transdifferentiation of fibroblasts to neurons (see Fig. 1),
avoiding a pluripotent ‘in between-stage’. This approach,
although in a yet premature phase, shows a highly interest-
ing option to generate DA neurons, circumventing some of
the most critical pitfalls of the iPSC technology. In 2010,
researchers described the possibility to manipulate mouse
fibroblasts by introducing three neurodevelopmental factors
(Brn2, Ascl1 and Myth1l) in such a way that they directly
converted into neuronal cells, so called induced neurons, or
iNs [59]. Shortly after that, the same group reported the
same achievement for human fibroblasts [60]. Both, mouse
and human iNs showed expression of neuronal markers such
as Tuj1, Map2, Tau and synapsin and revealed neuron-like
electrophysiological properties.
In a more PD relevant approach two groups showed that
the combination of the above mentioned iN factors com-
bined with Lmx1a and FoxA2 [61] or a combination of
Lmx1a and Nurr1 [62] in fibroblasts is sufficient to directly
induce cells with DA neuronal characteristics, therefore
called iDA neurons.
The combination of the three neurodevelopmental factors
(BAM) with factors known to be crucially involved in the
embryonic development of mDA neurons as well as for their
beneficial effect for DA differentiation of ESCs [63–68]
seem to specifically boost the transdifferentiation towards
DA-like neurons. Even though these findings provide a
proof of principle for the amazing possibility to directly
transdifferentiate/convert somatic cells just by simple forced
expression of a specific set of transcription factors, also for
iDA neurons a very thorough characterization would be
necessary before one could seriously consider their clinical
application.
For a better understanding of to what extent iDA neurons
are similar to primary midbrain DA neurons, the use of
transgenic Pitx3-GFP mice, as described above for iPSCs,
can be an adequate tool. Kim et al. [69] used tail tip fibro-
blasts from transgenic Pitx3-GFP mice for transdifferentia-
tion experiments [69]. iDA neurons were isolated based on
GFP expression and gene expression was compared to pri-
mary midbrain DA neurons (equally positive for Pitx3-
GFP). Comparison of a selected list of markers for DA
neurons showed only limited similarities between iDA and
primary DA neurons. However, Pitx3-GFP sorted iDA neu-
rons showed dopamine release, acquired highly similar
electrophysiological properties and showed functional inte-
gration in 6-OHDA lesioned mice.
Taken together, the possibility to directly convert somatic
cells into neurons might provide a valuable tool to study
diseases like PD in vitro. Besides, when issues such as the
conversion efficiency and the not yet optimal genotypic and
phenotypic characteristics are solved and improved, iDA
neurons could provide a cell replacement tool as well.
Concluding Remarks
The full scope of iPSC-based technology in terms of in vitro
disease modeling as well as in regenerative medicine
becomes more and more apparent. This might in particular
be the case for approaches to treat Parkinson’s disease. We
strongly believe that future research in this exciting field
will provide much more details about disease-causing
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factors, at cellular as well as environmental level. In addi-
tion, a clinically safe generation of human iPSCs and the
subsequent in vitro generation of patient specific DA neu-
rons might provide realistic tools to replace lost DA neurons
in PD patients. Last but not least the sheer possibility to
generate specific DA neurons directly from patient fibro-
blasts opens up a completely new angle concerning cellular
PD research.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution License which permits any use, distribution,
and reproduction in any medium, provided the original author(s) and
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